Global prevalence of polypharmacy among the COVID-19 patients: A comprehensive systematic review and meta-analysis of observational studies

Hooman Ghasemi; Niloofar Darvishi; Nader Salari; Amin Hosseinian Far; Hakimeh Akbari; Masoud Mohammadi

doi:10.1186/s41182-022-00456-x

Global prevalence of polypharmacy among the COVID-19 patients: A comprehensive systematic review and meta-analysis of observational studies

Hooman Ghasemi, Niloofar Darvishi, Nader Salari, Amin Hosseinian Far, Hakimeh Akbari, Masoud Mohammadi

Hertfordshire Business School

Research output: Contribution to journal › Article › peer-review

1 Downloads (Pure)

Abstract

BACKGROUND: Polypharmacy has traditionally been defined in various texts as the use of 5 or more chronic drugs, the use of inappropriate drugs, or drugs that are not clinically authorized. The aim of this study was to evaluate the prevalence of polypharmacy among the COVID-19 patients, and the side effects, by systematic review and meta-analysis.METHODS: This study was performed by systematic review method and in accordance with PRISMA 2020 criteria. The protocol in this work is registered in PROSPERO (CRD42021281552). Particular databases and repositories have been searched to identify and select relevant studies. The quality of articles was assessed based on the Newcastle-Ottawa Scale checklist. Heterogeneity of the studies was measured using the I 2 test. RESULTS: The results of meta-analysis showed that the prevalence of polypharmacy in 14 studies with a sample size of 189,870 patients with COVID-19 is 34.6% (95% CI: 29.6-40). Studies have shown that polypharmacy is associated with side effects, increased morbidity and mortality among patients with COVID-19. The results of meta-regression analysis reported that with increasing age of COVID-19 patients, the prevalence of polypharmacy increases (p

Original language	English
Article number	60
Pages (from-to)	1-12
Number of pages	12
Journal	Tropical Medicine and Health
Volume	50
Issue number	1
DOIs	https://doi.org/10.1186/s41182-022-00456-x
Publication status	Published - 31 Aug 2022

Keywords

Covid-19
Increased Morbidity And Mortality
Meta-analysis
Polypharmacy
Prevalence

Access to Document

10.1186/s41182-022-00456-xLicence: CC BY

Final_Version
© 2022 The Author(s). This is an open access article under the Creative Commons Attribution-NonCommercial-NoDerivatives CC BY-NC-ND licence, https://creativecommons.org/licenses/by-nc-nd/4.0/
Final published version, 1.6 MBLicence: CC BY

Cite this

@article{35926f1ed3ee4d5887025ef6bf828d7f,

title = "Global prevalence of polypharmacy among the COVID-19 patients: A comprehensive systematic review and meta-analysis of observational studies",

abstract = "BACKGROUND: Polypharmacy has traditionally been defined in various texts as the use of 5 or more chronic drugs, the use of inappropriate drugs, or drugs that are not clinically authorized. The aim of this study was to evaluate the prevalence of polypharmacy among the COVID-19 patients, and the side effects, by systematic review and meta-analysis.METHODS: This study was performed by systematic review method and in accordance with PRISMA 2020 criteria. The protocol in this work is registered in PROSPERO (CRD42021281552). Particular databases and repositories have been searched to identify and select relevant studies. The quality of articles was assessed based on the Newcastle-Ottawa Scale checklist. Heterogeneity of the studies was measured using the I 2 test. RESULTS: The results of meta-analysis showed that the prevalence of polypharmacy in 14 studies with a sample size of 189,870 patients with COVID-19 is 34.6% (95% CI: 29.6-40). Studies have shown that polypharmacy is associated with side effects, increased morbidity and mortality among patients with COVID-19. The results of meta-regression analysis reported that with increasing age of COVID-19 patients, the prevalence of polypharmacy increases (p ",

keywords = "Covid-19, Increased Morbidity And Mortality, Meta-analysis, Polypharmacy, Prevalence",

author = "Hooman Ghasemi and Niloofar Darvishi and Nader Salari and {Hosseinian Far}, Amin and Hakimeh Akbari and Masoud Mohammadi",

note = "{\textcopyright} 2022 The Author(s). This is an open access article under the Creative Commons Attribution-NonCommercial-NoDerivatives CC BY-NC-ND licence, https://creativecommons.org/licenses/by-nc-nd/4.0/",

year = "2022",

month = aug,

day = "31",

doi = "10.1186/s41182-022-00456-x",

language = "English",

volume = "50",

pages = "1--12",

journal = "Tropical Medicine and Health",

issn = "1348-8945",

publisher = "BioMed Central (BMC)",

number = "1",

}

TY - JOUR

T1 - Global prevalence of polypharmacy among the COVID-19 patients: A comprehensive systematic review and meta-analysis of observational studies

AU - Ghasemi, Hooman

AU - Darvishi, Niloofar

AU - Salari, Nader

AU - Hosseinian Far, Amin

AU - Akbari, Hakimeh

AU - Mohammadi, Masoud

PY - 2022/8/31

Y1 - 2022/8/31

N2 - BACKGROUND: Polypharmacy has traditionally been defined in various texts as the use of 5 or more chronic drugs, the use of inappropriate drugs, or drugs that are not clinically authorized. The aim of this study was to evaluate the prevalence of polypharmacy among the COVID-19 patients, and the side effects, by systematic review and meta-analysis.METHODS: This study was performed by systematic review method and in accordance with PRISMA 2020 criteria. The protocol in this work is registered in PROSPERO (CRD42021281552). Particular databases and repositories have been searched to identify and select relevant studies. The quality of articles was assessed based on the Newcastle-Ottawa Scale checklist. Heterogeneity of the studies was measured using the I 2 test. RESULTS: The results of meta-analysis showed that the prevalence of polypharmacy in 14 studies with a sample size of 189,870 patients with COVID-19 is 34.6% (95% CI: 29.6-40). Studies have shown that polypharmacy is associated with side effects, increased morbidity and mortality among patients with COVID-19. The results of meta-regression analysis reported that with increasing age of COVID-19 patients, the prevalence of polypharmacy increases (p

AB - BACKGROUND: Polypharmacy has traditionally been defined in various texts as the use of 5 or more chronic drugs, the use of inappropriate drugs, or drugs that are not clinically authorized. The aim of this study was to evaluate the prevalence of polypharmacy among the COVID-19 patients, and the side effects, by systematic review and meta-analysis.METHODS: This study was performed by systematic review method and in accordance with PRISMA 2020 criteria. The protocol in this work is registered in PROSPERO (CRD42021281552). Particular databases and repositories have been searched to identify and select relevant studies. The quality of articles was assessed based on the Newcastle-Ottawa Scale checklist. Heterogeneity of the studies was measured using the I 2 test. RESULTS: The results of meta-analysis showed that the prevalence of polypharmacy in 14 studies with a sample size of 189,870 patients with COVID-19 is 34.6% (95% CI: 29.6-40). Studies have shown that polypharmacy is associated with side effects, increased morbidity and mortality among patients with COVID-19. The results of meta-regression analysis reported that with increasing age of COVID-19 patients, the prevalence of polypharmacy increases (p

KW - Covid-19

KW - Increased Morbidity And Mortality

KW - Meta-analysis

KW - Polypharmacy

KW - Prevalence

U2 - 10.1186/s41182-022-00456-x

DO - 10.1186/s41182-022-00456-x

M3 - Article

SN - 1348-8945

VL - 50

SP - 1

EP - 12

JO - Tropical Medicine and Health

JF - Tropical Medicine and Health

IS - 1

M1 - 60

ER -

Global prevalence of polypharmacy among the COVID-19 patients: A comprehensive systematic review and meta-analysis of observational studies

Abstract

Keywords

Access to Document

Fingerprint

Cite this